Medical Hypotheses
Volume 59, Issue 3 , Pages 233-238 , September 2002

Establishment, maintenance, and remodeling of curvature in biology

  • E Fosslien

      Affiliations

    • Corresponding Author InformationCorrespondence to: E. Fosslien MD, Department of Pathology (M/C 847), College of Medicine, University of Illinois at Chicago, 1819 West Polk Street, Chicago, IL 60612, USA. Phone: 312-996-7323; Fax: 312-996-7586

Received 17 October 2001 ,Accepted 20 December 2001.

References 

  1. Reddi AH. Bone morphogenetic proteins and skeletal development: the kidney-bone connection. Pediatr. Nephrol. 2000;14:598–601
  2. Hirai Y, Radisky D, Boudreau R, Simian M, Stevens ME, Oka Y, et al. Epimorphin mediates mammary luminal morphogenesis through control of C/EBPbeta. J. Cell Biol. 2001;153:785–794
  3. Millan FA, Denhez F, Kondaiah P, Akhurst RJ. Embryonic gene expression patterns of TGF beta 1, beta 2 and beta 3 suggest different developmental functions in vivo. Development. 1991;111:131–143
  4. Fosslien E. Molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. Ann. Clin. Lab. Sci. 2001;31:325–348 (in press)
  5. Battegay EJ, Raines EW, Seifert RA, Bowen-Pope DF, Ross R. TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell. 1990;63:515–524
  6. Björkerud S. Effects of transforming growth factor-beta 1 on human arterial smooth muscle cells in vitro. Arterioscler. Thromb. 1991;11:892–902
  7. Pepper MS, Vassalli JD, Orci L, Montesano R. Biphasic effect of transforming growth factor-beta 1 on in vitro angiogenesis. Exp. Cell Res. 1993;204:356–363
  8. Qiu L. Regulatory role of hormones and growth factors in the pathophysiology of human uterine leiomyomas. Ph.D. Thesis, Graduate College of the UIC Health Sciences Center, University of Illinois at Chicago, 1995
  9. Fosslien E, Lin Q, Yamashiroya H. Human uterine leiomyoma cells: growth responses to epidermal growth factor and transforming growth factor beta. Ann. Clin. Lab. Sci. 1997;27:318–319
  10. Potter JD. Morphostats: a missing concept in cancer biology. Cancer Epidemiol. Biomarkers Prev. 2001;10:161–170
  11. Jones CM, Armes N, Smith JC. Signaling by TGF-beta family members: short-range effects of Xnr-2 and BMP-4 contrast with the long-range effects of activin. Curr. Biol. 1996;6:1468–1475
  12. McDowell N, Gurdon JB, Grainger DJ. Formation of a functional morphogen gradient by a passive process in tissue from the early Xenopus embryo. Int. J. Dev. Biol. 2001;45:199–207
  13. Papageorgiou S. A physical force may expose Hox genes to express in a morphogenetic density gradient. Bull. Math. Biol. 2001;63:185–200
  14. Yamashita H, Tobari I, Sawa M, et al.  Functions of the transforming growth factor-beta superfamily in eyes. Nippon Ganka Gakkai Zasshi. 1997;101:927–947
  15. Onichtchouk D, Chen YG, Dosch R, et al.  Silencing of TGF-beta signaling by the pseudoreceptor BAMBI. Nature. 1999;401:480–485
  16. Cardillo MR, Yap E. TGF-beta 1 in colonic neoplasia: a genetic molecular and immunohistochemical study. J. Exp. Clin. Cancer Res. 1997;16:281–288
  17. Iseki S, Osumi-Yamashita N, et al.  Localization of transforming growth factor-beta type I and type II receptors in mouse development. Exp. Cell Res. 1995;219:339–347
  18. Madri JA, Pratt BM, Tucker AM. Phenotypic modulation of endothelial cells by transforming growth factor-beta depends upon the composition and organization of the extracellular matrix. J. Cell Biol. 1988;106:1375–1384
  19. Roberts AB, Sporn MB. Regulation of endothelial cell growth, architecture, and matrix synthesis by TGF-beta. Am. Rev. Respir. Dis. 1989;140:1126–1128
  20. Dickson M. C., Martin J. S., Cousins F. M., Kulkarni A. B., Karlsson S., Akhurst R. J. Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1
  21. Arciniegas E, Ponce L, Hartt Y, Graterol A, Carlini RG. Intimal thickening involves transdifferentiation of embryonic endothelial cells. Anat. Rec. 2000;258:47–57
  22. Song J, Rolfe BE, Hayward IP, Campbell GR, Campbell JH. Effects of collagen gel configuration on behavior of vascular smooth muscle cells in vitro: association with vascular morphogenesis. In Vitro Cell Dev. Biol. Anim. 2000;36:600–610
  23. Zheng W, Seftor EA, Meininger CJ, Hendrix MJ, Tomanek RJ. Mechanisms of coronary angiogenesis in response to stretch: role of VEGF and TGF-beta. Am. J. Physiol. Heart Circ. Physiol. 2001;280:H909–H917
  24. Assoian RK, Sporn MB. Type beta transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells. J. Cell Biol. 1986;102:1217–1223
  25. Azuma H. Genetic and molecular pathogenesis of hereditary hemorrhagic telangiectasia. J. Med. Invest. 2000;47:81–90
  26. Keerthisingam CB, Jenkins RG, Harrison NK, et al.  Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonnary fibrosis in mice. Am. J. Pathol. 2001;158:1411–1422
  27. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann. Clin. Lab. Sci. 2000;30:3–21
  28. Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit. Rev. Clin. Lab. Sci. 2000;37:431–502
  29. Debons AF, Fani K, Jimenez FA. Enhancement of experimental atherosclerosis by aspirin. J. Toxicol. Environ. Health. 1981;8:899–906
  30. Sato Y, Kobori S, Sakai M, et al.  Lipoprotein (a) induces cell growth in rat peritoneal macrophages through inhibition of transforming growth factor-beta activation. Atherosclerosis. 1996;125:15–26
  31. Kojima S, Harpel PC, Rifkin DB. Lipoprotein (a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J. Cell Biol. 1991;113:1439–1445
  32. Nagai Y, Tasaki H, Takatsu H, et al.  Homocysteine inhibits angiogenesis in vitro and in vivo. Biochem. Biophys. Res. Commun. 2001;281:726–731
  33. Rosenquist TH, Ratashak SA, Selhub J. Homocysteine induces congenital defects of the heart and neural tube: effect of folic acid. Proc. Natl. Acad. Sci. USA. 1996;93:15227–15232
  34. McCaffrey TA. TGF-betas and TGF-beta receptors in atherosclerosis. Cytokine Growth Factor Rev. 2000;11:103–114
  35. McCaffrey TA, Falcone DJ. Evidence for an age-related dysfunction in the antiproliferative response to transforming growth factor-beta in vascular smooth muscle cells. Mol. Biol. Cell. 1993;4:315–322
  36. Guda K, Giardina C, Nambiar P, Cui H, Rosenberg DW. Aberrant transforming growth factor-beta signaling in azoxymethane-induced mouse colon tumors. Mol. Carcinog. 2001;31:204–213
  37. Ripamonti U, Tasker JR. Advances in biotechnology for tissue engineering of bone. Curr. Pharm. Biotechnol. 2000;1:47–55
  38. Miyazono K, Heldin CH. Structure, function and possible clinical application of transforming growth factor-beta. J. Dermatol. 1992;19:644–647
  39. Lindner V. Vascular repair processes mediated by transforming growth factor-beta. Z. Kardiol. 2001;90(suppl. 3):17–22
  40. Smith JD, Bryant SR, Couper LL, et al.  Soluble transforming growth factor-beta type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth. Circ. Res. 1999;84:1212–1222

PII: S0306-9877(02)00206-2

Medical Hypotheses
Volume 59, Issue 3 , Pages 233-238 , September 2002

Article Tools

* Image Usage & Resolution